Neue Hormontherapien beim metastasierten Prostatakarzinom

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2012) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. Int J Cancer 136:E359–86 Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232–240 Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L et al (2011) The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. Embo J 30:2719–2733 Dillard PR, Lin MF, Khan SA (2008) Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 295:115–120 Culig Z, Santer FR (2014) Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev 33:413–427 Hu J, Wang G, Sun T (2017) Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives. Tumour Biol 39:1010428317692259 Krakowsky Y, Morgentaler A (2019) Risk of testosterone flare in the era of the saturation model: one more historical myth. Eur Urol Focus 5:81–89 Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79:263–282 Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R et al (2020) Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 382:2187–2196 Margel D, Peer A, Ber Y, Shavit-Grievink L, Tabachnik T, Sela S et al (2019) Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J Urol 202:1199–1208 Kunath F, Grobe HR, Rucker G, Motschall E, Antes G, Dahm P et al (2015) Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review. BJU Int 116:30–36 Virgo KS, Rumble RB, de Wit R, Mendelson DS, Smith TJ, Taplin ME et al (2021) Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: aSCO guideline update. J Clin Oncol 39:1274–1305 Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL et al (2014) Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol 32:3705–3715 James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338–351 Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352–360 Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381:121–131 Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13–24 Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378:1408–1418 Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN et al (2021) Apalutamide and overall survival in prostate cancer. Eur Urol 79:150–158 Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF et al (2020) Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 382:2197–2206 Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U et al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378:2465–2474 Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S et al (2019) Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 380:1235–1246 Fizazi K, Shore ND, Tammela T, Ulys A, Vjaters E, Polyakov S et al (2020) Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol 38:5514 Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152–160 Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148 Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P et al (2014) Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 66:815–825 Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433